Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising results in initial clinical studies. Current https://bookmarkpressure.com/story21284202/retatrutide-emerging-investigations-and-potential-medical-roles